Dose Response of Fractional Exhaled Nitric Oxide (FeNO) to Inhaled Steroids in Mild-to-moderate Asthma

This study has been completed.
Information provided by (Responsible Party):
Brian J Lipworth, University of Dundee Identifier:
First received: October 14, 2009
Last updated: June 11, 2012
Last verified: June 2012
Asthma is a chronic disease, which means that it cannot be cured, but the investigators can use inhalers and tablets to control the symptoms. In asthma, the airways become inflamed and irritated which can cause coughing and make the airways tighten. This 'inflammation' is the root of the problem in asthma. Doctors have different ways to measure the inflammation in the airways. One way is to measure a gas called nitric oxide (NO) on the breath. This is made by the lungs when asthmatic inflammation is present. The investigators have been using NO as a test in research labs for many years, but there are still unanswered questions about how it changes between morning and night and how quickly medicines work on it. In most asthmatics, even small doses of inhaled steroids (preventers) can reduce the NO levels to normal, but in some people this does not seem to happen. The investigators now have portable NO machines that are designed for patients to use in the home. The investigators want to follow NO readings in patients with high levels to measure how they respond to different doses of steroid inhalers. The investigators hope this will help the investigators better understand asthma inflammation and treatments.

Condition Intervention Phase
Drug: Fluticasone Propionate
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Dose Response of FENO to Inhaled Steroids in Mild-to-moderate Asthma

Resource links provided by NLM:

Further study details as provided by University of Dundee:

Primary Outcome Measures:
  • Change in FENO [ Time Frame: 2 weeks ] [ Designated as safety issue: No ]

Enrollment: 21
Study Start Date: October 2009
Study Completion Date: December 2011
Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: High dose ICS
Fluticasone Propionate 250mcg bid
Drug: Fluticasone Propionate
Inhaled Fluticasone Propionate 250mcg bid
Active Comparator: Low dose ICS
Fluticasone propionate 50mcg bid
Drug: Fluticasone Propionate
Inhaled Fluticasone Propionate 50mcg bid


Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis os asthma, taking 200-1000mcg budesonide or equivalent per day
  • FENO greater than 30ppb on treatment

Exclusion Criteria:

  • Recent RTI or prednisolone
  • Smoking within 1 year or 10 pack years
  • ABPA, COPD, bronchiectasis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00995657

United Kingdom
Asthma and Allergy Research Group, University of Dundee
Dundee, Tayside, United Kingdom, DD1 9SY
Sponsors and Collaborators
University of Dundee
Principal Investigator: Peter A Williamson, MBChB University of Dundee
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Brian J Lipworth, Professor, University of Dundee Identifier: NCT00995657     History of Changes
Other Study ID Numbers: PAW003 
Study First Received: October 14, 2009
Last Updated: June 11, 2012
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency
United Kingdom: Research Ethics Committee

Additional relevant MeSH terms:
Bronchial Diseases
Hypersensitivity, Immediate
Immune System Diseases
Lung Diseases
Lung Diseases, Obstructive
Respiratory Hypersensitivity
Respiratory Tract Diseases
Anti-Allergic Agents
Anti-Asthmatic Agents
Anti-Inflammatory Agents
Autonomic Agents
Bronchodilator Agents
Dermatologic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Respiratory System Agents processed this record on May 26, 2016